PLI To Present Developments In Pharmaceutical And Biotech Patent Law

Tuesday, September 1, 2009 - 01:00

PLI has scheduled a program, Developments in Pharmaceutical and Biotech Patent Law 2009, to take place on Thursday, September 17 from 9 a.m to 5 p.m. at the PLI New York Center, 810 Seventh Avenue.

The presenters will be Karen I. Boyd, Turner Boyd LLP; Jennifer Gordon, Baker Botts L.L.P.; Timothy R. Holbrook, professor at law, Emory University School of Law; Lisa A. Schneider, Sidley Austin LLP; Gerald Sobel, Kaye Scholer LLP; Darryl L. Webster, senior patent counsel, Wyeth; Cynthia H. Zhang, director, Intellectual Property, Gilead Sciences Inc.

This program offers an opportunity to fully understand the impact of appellate decisions and the pending patent legislation on pharmaceutical and biotechnology patent law.

Participants will learn about the patentability of pharmaceutical products post -KSR v. Teleflex from the Federal Circuit and District Court perspectives; inequitable conduct in biotechnology and pharmaceutical patent cases; recent Supreme Court and Federal Circuit developments; Section 112 developments regarding enablement and written description requirements: the impact ofU.S. Patent and Trademark Office (USPTO) developments; written description guidelines; cutting-edge issues impacting your pharma and biotech patent prosecution practice; and patent misuse and other issues in pharma and biotech licensing.

For information about available CLE credits and fees, see CLE Events on The Metropolitan Corporate Counsel website at www.metrocorpcounsel.com.

To register for the program, visit www.pli.edu.